[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356223-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356223-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapy-induced-mrna-rrna-and-trna-methylation-alterations-confer-tolerance-phenotype-in-tumor-cells-mechanism-and-implications","Therapy-induced mRNA, rRNA and tRNA methylation alterations confer tolerance phenotype in tumor cells - mechanism and implications","","Drug tolerant persister cells (DTPs) represent a transient subpopulation that survives therapeutic pressure and reflects phenotype plasticity and heterogeneity. This review explains how epitranscriptomic regulation, especially RNA methylation, provides a non-genetic mechanism governing post-transcriptional gene-expression control across mRNA, tRNA and rRNA. By organizing RNA methylation patterns, the article links modified RNAs to DTP generation and progression, including epithelial-mesenchymal transition, metabolic shifts and immune escape. It further outlines therapy-prevention strategies using pharmacological RNA-modifying-enzyme modulators with lifestyle advice.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapy-induced-mrna-rrna-and-trna-methylation-alterations-confer-tolerance-phenotype-in-tumor-cells-mechanism-and-implications/356223/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapy-induced-mrna-rrna-and-trna-methylation-alterations-confer-tolerance-phenotype-in-tumor-cells-mechanism-and-implications/356223.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are drug tolerant persister cells (DTPs) in cancer therapy?","Question",{"text":63,"@type":64},"DTPs are a transient subpopulation of cancer cells with a drug-tolerance phenotype. They reflect phenotype plasticity and heterogeneity and can transition toward restored drug sensitivity or permanent drug resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does RNA methylation relate to DTP formation and development?",{"text":68,"@type":64},"RNA methylation is described as a key epitranscriptomic mechanism controlling post-transcriptional gene expression across mRNA, tRNA and rRNA. The review links methylation pattern changes to the generation and development of DTPs.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical strategies does the review propose to prevent DTP-driven tumor relapse?",{"text":72,"@type":64},"The review proposes pharmacological modulators targeting RNA-modifying enzymes, combined with non-pharmaceutical lifestyle advice. The goal is to develop therapy strategies that prevent relapse rooted in DTP formation and persistence.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356223,1790197677,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2026; 22(1): 86-110. doi: 10.7150/ijbs.120764  \nReview  \nTherapy-induced mRNA, rRNA and tRNA methylation alterations confer tolerance phenotype in tumor cells: mechanism and implications  \nAnfeng Jiang1, 2†, Shujie Liu 1†, Zhiyuan Li1, Xiongzhou Zhang2, Minghao Duan1, 3􀀍, Bin Li1, 4, 5􀀍  \n1. Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, People’s Republic of China.  \n2. Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, People’s Republic of China.  \n3. Department of Public Health Laboratory Sciences, School of Public Health, Hengyang Medical School, University of South China, Hengyang, 412017, Hunan, People’s Republic of China.  \n4. National Clinical Research Center for Geriatric Disorders, Changsha 410008, Hunan, People’s Republic of China.  \n5. Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, Hunan, People’s Republic of China.  \n† These authors contributed equally to this work.  \n􀀍 Corresponding authors: [1625164018@qq.com](1625164018@qq.com); [bincsuxy@csu.edu.cn](bincsuxy@csu.edu.cn).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.07.02; Accepted: 2025.09.26; Published: 2026.01.01  \nAbstract  \nDrug tolerant persister cells (DTPs) refer to a transient drug-tolerance sub-population of cancer cells characteristics of phenotype plasticity and heterogeneity. This adaptive cell state is a critical transitional phase, standing on the crossroad that cancer cells reacquire drug sensitivity or enter into the permanent drug resistance. Emerging evidences indicate the epitranscriptomic regulations, particularly RNA methylations are the important mechanism underline post-transcriptional regulations of genes expression across all RNA species. RNA is integral to gene expression as messenger RNA (mRNA), transfer RNA (tRNA) and ribosomal RNA (rRNA), which play roles in transmitting information from DNA to the synthesis of functional proteins. Methylation modifications on these RNAs are prevalent and represent a well-recognized non-genetic mechanism, exerting multifaceted regulatory effects on nucleic acid metabolism, such as nucleotide precursor availability, RNA processing dynamics, sub-cellular localization, transcript stability and translational fidelity/ efficiency. This review systematically sorts out the relevant references, demonstrating recent advances on the knowledge of the patterns of methylation modifications on mRNA, tRNA and rRNA, and how these modifications drive the generation and development of DTPs, which hallmarks of epithelial-mesenchymal transition, metabolism shift and immune escape. And then clinical strategies are delineated, leveraging pharmacological modulators of RNA-modifying enzymes alongside non-pharmaceutical lifestyle advice, for the development of therapy strategies preventing DTPs-rooted tumor relapse in this anti-tumor armamentarium with cytotoxic reagents, targeted therapies and immunotherapies.  \nKeywords: RNA, methylation, drug tolerant tumor cells, clinical strategies  \n1. Introduction  \nEarly in the 1900s, the initial application of nitro compounds as cytotoxic agents to treat leukemia marked a milestone in systemic cancer therapy. Since then, this therapeutic approach has been evolving continuously, evidenced by recent advancements in oncogene-targeted therapies and T-cells-centered immunotherapies, heralding a new era of precision medicine. However, the current standard treatments confer unprecedented benefits to a minority of cancer patients, while the majority still face incurable disease  \nwith enigmatic ","cbCaiutYRv7H2nnp","https://ap.wps.com/l/cbCaiutYRv7H2nnp","pdf",2541551,25,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What are drug tolerant persister cells (DTPs) in cancer therapy?\",\"answer\":\"DTPs are a transient subpopulation of cancer cells with a drug-tolerance phenotype. They reflect phenotype plasticity and heterogeneity and can transition toward restored drug sensitivity or permanent drug resistance.\"},{\"question\":\"How does RNA methylation relate to DTP formation and development?\",\"answer\":\"RNA methylation is described as a key epitranscriptomic mechanism controlling post-transcriptional gene expression across mRNA, tRNA and rRNA. The review links methylation pattern changes to the generation and development of DTPs.\"},{\"question\":\"What clinical strategies does the review propose to prevent DTP-driven tumor relapse?\",\"answer\":\"The review proposes pharmacological modulators targeting RNA-modifying enzymes, combined with non-pharmaceutical lifestyle advice. The goal is to develop therapy strategies that prevent relapse rooted in DTP formation and persistence.\"}]","Therapy-induced mRNA, rRNA and tRNA methylation alterations confer tolerance phenotype in tumor cells - mechanism and implications | PDF",1790124177,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc7e0ed9994e832de765b2db5b6a0706.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1034554eb5901fbed3a43b6c658095ba.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc2f1971c218bfacbce1c7dbad24c4d4.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8bf26b2596755596e237cd1d3e6be16.webp",980,1268]